Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations.

Blood Cancer J · 2025 · PMC12078594 · PMID 40368916

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

showed a trendp = 0.09so close (0.05 < p ≤ 0.1)

16.4 months, p = 0.06) compared to other AML subtypes, while those receiving VenHMA as frontline therapy showed a trend for better OS (18.9 months vs. 11.9 months, p = 0.09) and LFS (14.1 months vs. 7.8 months, p = 0.06).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.